171 related articles for article (PubMed ID: 36145306)
1. Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [
Plas P; Limana L; Carré D; Thiongane A; Raguin O; Mansi R; Meyer-Losic F; Lezmi S
Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145306
[TBL] [Abstract][Full Text] [Related]
2. Comparison of
Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry and pharmacokinetics of [
Schürrle SB; Eberlein U; Ansquer C; Beauregard JM; Durand-Gasselin L; Grønbæk H; Haug A; Hicks RJ; Lenzo NP; Navalkissoor S; Nicolas GP; Pais B; Volteau M; Wild D; McEwan A; Lassmann M
Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38528164
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of the safety and efficacy of [
Wild D; Grønbæk H; Navalkissoor S; Haug A; Nicolas GP; Pais B; Ansquer C; Beauregard JM; McEwan A; Lassmann M; Pennestri D; Volteau M; Lenzo NP; Hicks RJ
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):183-195. PubMed ID: 37721581
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist
Reidy-Lagunes D; Pandit-Taskar N; O'Donoghue JA; Krebs S; Staton KD; Lyashchenko SK; Lewis JS; Raj N; Gönen M; Lohrmann C; Bodei L; Weber WA
Clin Cancer Res; 2019 Dec; 25(23):6939-6947. PubMed ID: 31439583
[TBL] [Abstract][Full Text] [Related]
6. Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [
Mansi R; Plas P; Vauquelin G; Fani M
Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959665
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [
Zellmer J; Yen HY; Kaiser L; Mille E; Gildehaus FJ; Böning G; Steiger K; Hacker M; Bartenstein P; Todica A; Haug AR; Ilhan H
EJNMMI Res; 2020 Apr; 10(1):41. PubMed ID: 32335736
[TBL] [Abstract][Full Text] [Related]
8.
Thakur S; Daley B; Millo C; Cochran C; Jacobson O; Lu H; Wang Z; Kiesewetter D; Chen X; Vasko V; Klubo-Gwiezdzinska J
Clin Cancer Res; 2021 Mar; 27(5):1399-1409. PubMed ID: 33355247
[TBL] [Abstract][Full Text] [Related]
9. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
[TBL] [Abstract][Full Text] [Related]
10. Relationships between uptake of [
Stenvall A; Gustafsson J; Larsson E; Roth D; Sundlöv A; Jönsson L; Hindorf C; Ohlsson T; Sjögreen Gleisner K
EJNMMI Res; 2022 Dec; 12(1):75. PubMed ID: 36534192
[TBL] [Abstract][Full Text] [Related]
11. Lutetium [
Lastoria S; Rodari M; Sansovini M; Baldari S; D'Agostini A; Cervino AR; Filice A; Salgarello M; Perotti G; Nieri A; Campana D; Pellerito RE; Pomposelli E; Gaudieri V; Storto G; Grana CM; Signore A; Boni G; Dondi F; Simontacchi G; Seregni E
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38772998
[TBL] [Abstract][Full Text] [Related]
12. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
13. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [
Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A
Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
15.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors.
Zellmer J; Yen HY; Kaiser L; Gildehaus FJ; Böning G; Steiger K; Hacker M; Bartenstein P; Todica A; Haug AR; Ilhan H
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551858
[TBL] [Abstract][Full Text] [Related]
17. Intraindividual comparison of [
Hänscheid H; Hartrampf PE; Schirbel A; Buck AK; Lapa C
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2566-2572. PubMed ID: 33452632
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of [
Njotu FN; Ketchemen JP; Tikum AF; Babeker H; Gray BD; Pak KY; Uppalapati M; Fonge H
J Nucl Med; 2024 Apr; 65(4):533-539. PubMed ID: 38485273
[TBL] [Abstract][Full Text] [Related]
19. Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection.
Verburg FA; de Blois E; Koolen S; Konijnenberg MW
EJNMMI Phys; 2023 Nov; 10(1):69. PubMed ID: 37947917
[TBL] [Abstract][Full Text] [Related]
20. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
